Minerva Neurosciences, Inc.

Equities

NERV

US6033802058

Biotechnology & Medical Research

Delayed Nasdaq 01:45:42 2024-03-28 pm EDT 5-day change 1st Jan Change
2.52 USD +0.80% Intraday chart for Minerva Neurosciences, Inc. -2.70% -59.02%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sector Update: Health Care Stocks Ease Late Afternoon MT
Top Midday Decliners MT
Sector Update: Health Care Stocks Decline Tuesday Afternoon MT
Minerva Neurosciences Shares Tumble After FDA Rejects Roluperidone for Schizophrenia. MT
Minerva Neurosciences Shares Slide on Latest FDA Roluperidone Setback DJ
FDA Turns Away Minerva's Roluperidone Schizophrenia Drug DJ
Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia CI
Minerva Neurosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Minerva Neurosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Minerva Neurosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
HC Wainwright Adjusts Price Target on Minerva Neurosciences to $11 From $8, Maintains Neutral Rating MT
Minerva Neurosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Sector Update: Health Care Stocks Declining Late Wednesday MT
Sector Update: Health Care MT
Top Midday Gainers MT
Minerva Neurosciences to Raise $20 Million Through Private Placement of Common Shares MT
Minerva Neurosciences, Inc. announced that it expects to receive $19.999994 million in funding CI
Transcript : Minerva Neurosciences, Inc., Q1 2023 Earnings Call, May 15, 2023
Minerva Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
North American Morning Briefing : Hopes Build for -3- DJ
Minerva Neurosciences Says US FDA Accepts Filing of New Drug Application for Roluperidone to Treat Schizophrenia Symptoms MT
Minerva Neurosciences Gets FDA Confirmation for NDA for Roluperidone DJ
Minerva Neurosciences, Inc. Announces Board Changes CI
Top Midday Gainers MT
FDA Files Minerva Neurosciences's NDA for Roluperidone to Treat Schizophrenia Symptoms; Shares Jump 61% Midday MT
Chart Minerva Neurosciences, Inc.
More charts
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which focused on the development and commercialization of product candidates to treat patients suffering from central nervous system (CNS) diseases. It is engaged in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and have exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson's disease. It has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of the major depressive disorder (MDD). Roluperidone is a compound that blocks serotonin, sigma, and a-adrenergic receptors that are involved in the regulation of mood, cognition, sleep, and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1), protein, for the treatment of Parkinson's disease and for other neurodegenerative disorders.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
2.5 USD
Average target price
11 USD
Spread / Average Target
+340.00%
Consensus
  1. Stock
  2. Equities
  3. Stock Minerva Neurosciences, Inc. - Nasdaq
  4. News Minerva Neurosciences, Inc.
  5. Minerva Neurosciences Says FDA Doesn't Accept New Drug Application for Roluperidone; Shares Plunge Pre-Bell